PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $11,582,000 | -22.0% | 217,752 | -14.5% | 0.18% | -27.4% |
| Q2 2022 | $14,852,000 | -43.0% | 254,747 | -25.3% | 0.24% | -24.7% |
| Q1 2022 | $26,040,000 | +257.7% | 341,200 | +181.8% | 0.32% | +114.8% |
| Q3 2020 | $7,279,000 | +99.2% | 121,069 | +154.4% | 0.15% | +21.1% |
| Q4 2015 | $3,655,000 | +592.2% | 47,599 | +270.6% | 0.12% | +547.4% |
| Q3 2015 | $528,000 | -44.8% | 12,844 | -5.1% | 0.02% | -42.4% |
| Q2 2015 | $957,000 | -80.2% | 13,532 | -75.1% | 0.03% | -80.4% |
| Q1 2015 | $4,836,000 | -40.2% | 54,434 | -40.3% | 0.17% | -48.5% |
| Q4 2014 | $8,086,000 | +26.4% | 91,198 | +38.2% | 0.33% | +33.6% |
| Q3 2014 | $6,398,000 | +108.3% | 66,009 | +97.4% | 0.24% | +144.0% |
| Q2 2014 | $3,071,000 | +78.5% | 33,434 | -6.6% | 0.10% | +51.5% |
| Q3 2013 | $1,720,000 | +106.0% | 35,780 | +24.2% | 0.07% | +83.3% |
| Q2 2013 | $835,000 | – | 28,797 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |